GlassScriptPhysician profile
Hector Rodriguez
NPI 1013233097
$13,596.92
in general payments reported to CMS, 2019-2025
42 companies · $3,404 in 2025
The $3,404 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $973 · 2021: $1,804 · 2022: $2,398 · 2023: $2,012 · 2024: $2,234 · 2025: $3,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,154 · Education: $472 · Consulting Fee: $23.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,153.78 |
| Education | $472.19 |
| Consulting Fee | $23.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,832.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,768.02 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,240.21 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $1,233.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $683.04 | 2019-2025 | |
| Genentech USA, INC. | $679.61 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $650.20 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $613.16 | 2019-2025 | Dupixent |
| Csl Behring | $590.49 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Pfizer INC. | $514.84 | 2019-2025 | |
| Grifols USA, LLC | $352.56 | 2021-2025 | Xembify |
| Abbvie INC. | $343.98 | 2022-2024 | Rinvoq |
| Octapharma USA, INC. | $342.16 | 2024-2025 | Cutaquig, Panzyga |
| Hospira, INC. | $285.33 | 2021-2023 | |
| Amgen INC. | $280.29 | 2021-2025 | Tezspire, Uplizna |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $265.98 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $265.43 | 2021-2025 | Orladeyo |
| Incyte Corporation | $240.05 | 2021-2025 | Opzelura |
| Pharming Healthcare, INC. | $165.49 | 2021-2025 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.20 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $123.57 | 2022-2025 | Ryaltris |
| Aimmune Therapeutics, INC. | $106.12 | 2021-2022 | |
| Integra Lifesciences Corporation | $98.26 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Kaleo, INC. | $97.42 | 2021-2023 | Auvi-Q |
| Alk-Abello, INC | $94.44 | 2019-2023 | Odactra, Grastek, Ragwitek |
| Leo Pharma INC. | $82.94 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $72.72 | 2025 | Nemluvio |
| Organon LLC | $47.21 | 2025 | |
| Merck Sharp & Dohme LLC | $45.03 | 2021-2023 | |
| Cycle Pharmaceuticals INC | $44.25 | 2025 | Sajazir |
| Azurity Pharmaceuticals, INC. | $39.62 | 2025 | Alvesco |
| Ionis Pharmaceuticals, INC. | $39.51 | 2025 | Dawnzera |
| Shire North American Group INC | $36.11 | 2019 | |
| Aytu Biopharma, INC. | $33.18 | 2024-2025 | Karbinal |
| Adma Biomanufacturing LLC | $23.66 | 2025 | |
| Lilly USA, LLC | $22.37 | 2025 | Ebglyss |
| Gc Biopharma USA, INC. | $22.07 | 2025 | Alyglo |
| Verona Pharma, INC. | $19.34 | 2025 | Ohtuvayre |
| Blueprint Medicines Corporation | $15.91 | 2022 | |
| Phadia US INC. | $14.99 | 2023 | Immunocap |
| Eyevance Pharmaceuticals LLC | $13.07 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.